SEC Form SC 13D/A filed by Pulse Biosciences, Inc (Amendment)

$PLSE
Medical/Dental Instruments
Health Care
Get the next $PLSE alert in real time by email
SC 13D/A 1 sc13da1006922004_07022021.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

§ 240.13d-2(a)

(Amendment No. 10)1

Pulse Biosciences, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

74587B 10 1

(CUSIP Number)

ADAM W. FINERMAN, ESQ.

OLSHAN FROME WOLOSKY LLP

1325 Avenue of the Americas

New York, New York 10019

(212) 451-2300

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

 

June 30, 2021

(Date of Event Which Requires Filing of This Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.

Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7 for other parties to whom copies are to be sent.

 

 

 

1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

CUSIP No. 74587B 10 1

  1   NAME OF REPORTING PERSON  
         
        ROBERT W. DUGGAN  
  2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
        (b) ☐
           
  3   SEC USE ONLY    
           
           
  4   SOURCE OF FUNDS  
         
        PF  
  5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
       
           
  6   CITIZENSHIP OR PLACE OF ORGANIZATION  
         
        U.S.A  
NUMBER OF   7   SOLE VOTING POWER  
SHARES          
BENEFICIALLY         15,196,495*  
OWNED BY   8   SHARED VOTING POWER  
EACH          
REPORTING         - 0 -  
PERSON WITH   9   SOLE DISPOSITIVE POWER  
         
          15,196,495*  
    10   SHARED DISPOSITIVE POWER  
           
          - 0 -  
  11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
        15,196,495*  
  12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
       
           
  13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
        51.2%*  
  14   TYPE OF REPORTING PERSON  
         
        IN  

  

* Represents (i) 14,708,561 Shares, (ii) 157,915 Shares underlying options exercisable within 60 days hereof, held by Mr. Duggan and (iii) 330,019 Shares held by Genius Inc.

2

CUSIP No. 74587B 10 1

  1   NAME OF REPORTING PERSON  
         
        GENIUS INC.  
  2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
        (b) ☐
           
  3   SEC USE ONLY    
           
           
  4   SOURCE OF FUNDS  
         
        WC  
  5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
       
           
  6   CITIZENSHIP OR PLACE OF ORGANIZATION  
         
        DELAWARE  
NUMBER OF   7   SOLE VOTING POWER  
SHARES          
BENEFICIALLY         330,019  
OWNED BY   8   SHARED VOTING POWER  
EACH          
REPORTING         - 0 -  
PERSON WITH   9   SOLE DISPOSITIVE POWER  
         
          330,019  
    10   SHARED DISPOSITIVE POWER  
           
          - 0 -  
  11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
        330,019  
  12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
       
           
  13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
        1.1%  
  14   TYPE OF REPORTING PERSON  
         
        CO  

  

3

CUSIP No. 74587B 10 1

The following constitutes Amendment No. 10 to the Schedule 13D filed by the undersigned (the “Amendment No. 10”). This Amendment No. 10 amends the Schedule 13D as specifically set forth herein.

Item 3.Source and Amount of Funds or Other Consideration.

Item 3 is hereby amended and restated in its entirety to read as follows:

The aggregate purchase cost of the 14,332,496 Shares owned directly by Mr. Duggan is approximately $183,176,395, including brokerage commissions. 376,065 Shares owned by Mr. Duggan were acquired through the exercise of Warrants owned by Mr. Duggan, which were acquired in connection with the Offering. Such Shares and such Warrants were acquired with personal funds. Mr. Duggan received his stock options in connection with his service on the board of directors of the Issuer (the “Board”). 3,048,780 Shares (the “Private Placement Shares”) owned by Mr. Duggan were acquired pursuant to a Securities Purchase Agreement (the “Purchase Agreement”). Under the Purchase Agreement, the Issuer agreed to issue and sell to Mr. Duggan the Private Placement Shares in a private placement (the “Private Placement”), at a price per share of $16.40, the last reported sale price of the Issuer’s Shares on June 30, 2021, the immediately preceding trading day. The Private Placement Shares were paid for through (i) the conversion of $41 million aggregate principal amount, together with all accrued and unpaid interest outstanding, pursuant the Loan Agreement, and (ii) cash in the amount of approximately $8.4 million.

The aggregate purchase cost of the 321,805 Shares owned by Genius Inc., which Mr. Duggan is the sole shareholder of and may be deemed to be beneficially owned by Mr. Duggan, is approximately $4,139,693, including brokerage commissions. 8,214 Shares owned by Genius Inc. were acquired through the exercise of Warrants owned by Genius Inc., which were acquired in connection with the Offering. Such Shares and such Warrants were acquired with working capital.

Item 5.Interest in Securities of the Issuer.

Items 5(a)-(c) are hereby amended and restated in its entirety to read as follows:

The aggregate percentage of Shares reported owned by each person named herein is based upon (a) 29,509,133 Shares outstanding, which is the total number of Shares outstanding as of April 30, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on May 10, 2021, plus the Shares acquired by the Reported Person and reported hereby and (b) with respect to Mr. Duggan, 157,915 Shares underlying certain options exercisable within sixty days hereof.

A.Genius Inc.
(a)As of the close of business on July 2, 2021, Genius Inc. beneficially owned 330,019 Shares.

Percentage: Approximately 1.1%

(b)1. Sole power to vote or direct vote: 330,019
2. Shared power to vote or direct vote: 0
3. Sole power to dispose or direct the disposition: 330,019
4. Shared power to dispose or direct the disposition: 0

 

(c)Genius Inc. has not entered into any transactions in the Shares during the past sixty days.
4

CUSIP No. 74587B 10 1

B.Mr. Duggan
(a)As of the close of business on July 2, 2021, Mr. Duggan directly owned 14,866,476 Shares, including 157,915 Shares underlying options exercisable within sixty days hereof. In addition, as the sole shareholder of Genius Inc., Mr. Duggan may be deemed the beneficial owner of the 330,019 Shares owned by Genius Inc.

Percentage: Approximately 51.2%

(b)1. Sole power to vote or direct vote: 15,196,495
2. Shared power to vote or direct vote: 0
3. Sole power to dispose or direct the disposition: 15,196,495
4. Shared power to dispose or direct the disposition: 0

 

(c)Schedule A annexed hereto lists all transactions in the Shares of the Issuer by the Reporting Person since the filing of Amendment No. 9 to the Schedule 13D.
Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

Item 6 is hereby amended to add the following:

On June 30, 2021, Mr. Duggan and the Issuer entered into the Purchase Agreement. Under the Purchase Agreement, the Issuer agreed to issue and sell the Private Placement Shares to Mr. Duggan in the Private Placement. The Private Placement Shares were paid for through (i) the conversion of $41 million aggregate principal amount, together with all accrued and unpaid interest outstanding, pursuant the Loan Agreement, and (ii) cash in the amount of approximately $8.4 million. Upon closing of the Private Placement and satisfaction of the outstanding debt, the Loan Agreement will terminate, without early termination fees or penalties being owed by the Issuer, and no additional amounts will be owed to Mr. Duggan under the Loan Agreement.

The foregoing descriptions of the Purchase Agreement and the transactions contemplated thereby are not complete and are subject to and qualified in their entirety by reference to the Purchase Agreement attached hereto as Exhibit 99.1, and incorporated herein by reference.

Item 7.Material to be Filed as Exhibits.
99.1Securities Purchase Agreement, dated June 30, 2021, by and between the Issuer and the Reporting Person (incorporated by reference to Exhibit 10.1 of the Issuer’s Current Report on Form 8-K filed on July 1, 2021).

5

CUSIP No. 74587B 10 1

SIGNATURES

After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: July 2, 2021

 

  GENIUS INC.
   
  By:

/s/ Kathryn Zwan

    Name: Kathryn Zwan
    Title: Chief Financial Officer
   
   
 

/s/ Robert W. Duggan

  Robert W. Duggan

 

6

CUSIP No. 74587B 10 1

SCHEDULE A

Transactions in the Securities of the Issuer Since the Filing of Amendment No. 9 to the Schedule 13D

Class of

Security

Securities

Purchased/(Sold)

Price

Date of

Transaction

       
Purchase of Common Stock 3,048,780 $16.40 06/30/2021

 

 

Get the next $PLSE alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PLSE

DatePrice TargetRatingAnalyst
2/10/2022$43.00 → $20.00Buy
HC Wainwright & Co.
11/16/2021$46.00 → $43.00Buy
HC Wainwright & Co.
7/27/2021$28.00Overweight
Stephens & Co.
More analyst ratings

$PLSE
Press Releases

Fastest customizable press release news feed in the world

See more
  • Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2024. Recent Business Highlights Soft Tissue Ablation Announced positive preliminary results from its first-in-human feasibility study using Nanosecond Pulsed Field Ablation technology for the treatment of benign thyroid nodules at the North American Society for Interventional Thyroidology Annual Meeting. Advanced pilot program optimizing therapy delivery with 8 centers in the U.S. that are expected to begin commercial

    $PLSE
    Medical/Dental Instruments
    Health Care
  • Pulse Biosciences To Present at the 24th Annual Needham Virtual Health Care Conference

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced plans to present at the upcoming 24th Annual Needham Virtual Health Care Conference. Pulse Biosciences' Management is scheduled to present on Thursday, April 10, 2025, at 9:30 am ET. A live and recorded webcast of the presentation will be available on the "Events Calendar and Presentations" page of the company's investor website at http://investors.pulsebiosciences.com/. About Pulse Biosciences® Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as

    $PLSE
    Medical/Dental Instruments
    Health Care
  • Pulse Biosciences Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call for March 27, 2025

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced it will report financial results for the fourth quarter and full year 2024 after market close on Thursday, March 27, 2025. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by dialing 1-888-596-4144 and providing conference ID 5548579. A live and recorded webcast of the event will be available on the Pulse Biosciences Investors website at http://investors.pulsebiosciences.com/. About Pulse Biosciences® P

    $PLSE
    Medical/Dental Instruments
    Health Care

$PLSE
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$PLSE
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$PLSE
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$PLSE
SEC Filings

See more

$PLSE
Leadership Updates

Live Leadership Updates

See more
  • Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer

    Expanded executive team to support operational excellence and commercialization of the CellFX nanosecond PFA Platform Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced the appointment of Jon Skinner as Chief Financial Officer, effective February 3, 2025. "I am excited to announce Jon as our next CFO, further building upon our momentum at Pulse Biosciences. His experience as a financial leader at both growth stage and scaled public diversified medtech companies will be extremely valuable in our efforts to advance our nanosecon

    $AXTA
    $PLSE
    $TFX
    Paints/Coatings
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care
  • Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology

    Adds Andrea Natale, M.D. as a medical advisor, joining existing advisors Vivek Reddy, M.D. and Jacob Koruth, M.D. Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology. Andrea Natale, M.D. will become a medical advisor for the company, joining existing advisors Vivek Reddy, M.D. and Jacob Koruth, M.D., who altogether will continue to support the development and clinical efforts for the Pulse Biosciences nano-PFA 360 Cardiac Catheter. "I am inspired by the potential of nano-PFA and the unique catheter

    $PLSE
    Medical/Dental Instruments
    Health Care
  • Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

    Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of Paul A. LaViolette to its Board of Directors. Mr. LaViolette has been appointed Co-Chairman of the Board alongside Co-Chairman Robert W. Duggan, serving as an independent director. "We are thrilled to have Paul join the Pulse Biosciences Board. His track record speaks for itself as he has been influential in the medical tech

    $PLSE
    Medical/Dental Instruments
    Health Care

$PLSE
Financials

Live finance-specific insights

See more
  • Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2024. Recent Business Highlights Soft Tissue Ablation Announced positive preliminary results from its first-in-human feasibility study using Nanosecond Pulsed Field Ablation technology for the treatment of benign thyroid nodules at the North American Society for Interventional Thyroidology Annual Meeting. Advanced pilot program optimizing therapy delivery with 8 centers in the U.S. that are expected to begin commercial

    $PLSE
    Medical/Dental Instruments
    Health Care
  • Pulse Biosciences Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call for March 27, 2025

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced it will report financial results for the fourth quarter and full year 2024 after market close on Thursday, March 27, 2025. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by dialing 1-888-596-4144 and providing conference ID 5548579. A live and recorded webcast of the event will be available on the Pulse Biosciences Investors website at http://investors.pulsebiosciences.com/. About Pulse Biosciences® P

    $PLSE
    Medical/Dental Instruments
    Health Care
  • Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results

    Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA or nano-PFA) technology, today announced business updates and financial results for the third quarter ended September 30, 2024. Recent Business Highlights Soft Tissue Ablation Placed nsPFA Percutaneous Electrode Systems with seven sites in the U.S. as part of a pilot program for clinical assessment with commercial use expected to begin in the coming quarters. The Company expects to commence a pivotal clinical trial in mid-2025 to support a specific labeling indication to commercialize the Percutaneous Electrode System in

    $PLSE
    Medical/Dental Instruments
    Health Care

$PLSE
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more